ISIS PHARM(NSDQ:ISIS)
|
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discoveryand development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services.
|
# Employees: 300
|
|
Address: 1896 Rutherford Road,Carlsbad,CA,USA
|
|
Phone: 760 931-9200
|
Fax: 760 603-2700
|
|
Website: www.isispharm.com
|
Email: info@isisph.com
|
Sector: Medical
|
Industry: MED-BIOMED/GENE
|
Executive Officers
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
|
Last Earnings Date: 6/30/2008
|
|
Next Earnings Date(Expected): 11/6/2008
|
|
Mean EPS (Next Qtr): ($0.05)
|
|
Mean EPS (Year): ($0.17)
|
|
Mean Estimate(Long Term): ($0.01)
|
|
P/E Ratio(Based on EPS estimate): -0.010
|
|
Number of Estimates: 9
|
|
Shares Performance
|
Period
|
ISIS
|
Compare to S&P
|
| YTD |
17.46 %
|
33.47 %
|
| 4 Weeks |
12.67 %
|
9.66 %
|
| 12 Weeks |
30.83 %
|
41.79 %
|
Shares Information
|
Analyst Coverage: Y
|
Avg Volume: 1388656
|
|
Shares Outstanding: 95M
|
Market Cap: $1.76B
|
| 52 Week High: $19.08
|
52 Week Low: $11.14
|
| P/E Ratio: 205.560
|
PEG Ratio: -0.010
|
|
Split: On 1/1/1990 ISIS split by factor of 2.000
|
Earnings Performance
EPS Growth in Last Quarter: 60.00 %
EPS Growth in Last Year: 84.62 %
Sales Growth in Last Quarter: 54.36 %
Sales Growth in Last Quarter: 764.44 %
Financials
|
Qtr Book Value: $29.90
|
|
Cash Flow/Share: ($0.01)
|
|
Change in Payout Ratio: -0.010
|
|
Price/Sales: 15.000
|
|
